Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) fell 9.6% on Monday . The company traded as low as $7.17 and last traded at $7.30. 770,895 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 2,185,823 shares. The stock had previously closed at $8.07.
Analysts Set New Price Targets
Several research firms have recently issued reports on NTLA. Wedbush reaffirmed a "neutral" rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Truist Financial reduced their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company lowered their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $37.56.
Read Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Trading Up 9.6 %
The business has a fifty day moving average of $9.79 and a 200-day moving average of $13.48. The firm has a market cap of $755.67 million, a PE ratio of -1.34 and a beta of 1.97.
Insider Activity
In related news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 29,000 shares of company stock worth $352,551 over the last ninety days. Company insiders own 3.20% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. State Street Corp raised its position in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in Intellia Therapeutics by 125.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock worth $1,411,000 after acquiring an additional 67,276 shares during the last quarter. Patient Square Capital LP bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $2,642,000. Charles Schwab Investment Management Inc. raised its stake in Intellia Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock valued at $17,006,000 after purchasing an additional 37,714 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth $421,000. 88.77% of the stock is owned by institutional investors.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
